15th February 2018
article written by
Cell Medica

Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer

Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer to head up the Company’s international financial activities Kevin has over 20 years of diversified finance experience helping companies define and achieve strategic financial objectives.  He has broad international experience with both public and private companies and has raised over $2.0 billion in capital […]

Read Full Article
7th December 2017
article written by
Cell Medica

Cell Medica announces appointment of industry leader Dr Annalisa Jenkins as Chair

Dr Annalisa Jenkins is a life sciences business and thought leader with over 25 years of biopharmaceutical industry experience in advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Prior to joining Cell Medica, Dr Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company […]

Read Full Article
16th November 2017
article written by
Cell Medica

Cell Medica will present interim data from the ongoing CITADEL clinical trial of CMD-003 in patients with NKT lymphoma at the prestigious American Society of Hematology

Cell Medica will present interim data from the ongoing CITADEL clinical trial of CMD-003 in patients with NKT lymphoma at the prestigious American Society of Hematology conference in Atlanta on Monday, December 11, 2017, 6:00 PM-8:00 PM please click here to see full details https://ash.confex.com/ash/2017/webprogram/Paper101920.html

Read Full Article
18th September 2017
article written by
Cell Medica

Cell Medica announces the appointment of Luis Borges, PhD, as Chief Scientific Officer

Cell Medica Announces the appointment of Luis Borges, PhD, as Chief Scientific Officer to accelerate R&D for CAR and TCR programmes Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five […]

Read Full Article